Emanuela Caroli1, Michele Acqui, Luigi Ferrante. 1. Neurological Sciences Department, Neurosurgery, Policlinico S Andrea, University La Sapienza, Rome, Italy. manucarol2000@yahoo.it
Abstract
AIMS AND BACKGROUND: Primary CNS lymphomas are uncommon tumors in immunocompetent patients. We describe the radiological features that should orient towards performing a biopsy and analyze the results in our series of patients. METHODS: We reviewed 22 immunocompetent patients with primary central nervous system lymphoma admitted in our Institute between 1977 and 1997. The follow-up period ranged from 2 months (patient deceased) to 69 months. Fourteen patients underwent surgical removal of the tumor and the remainder a biopsy. All patients received radiotherapy and 8 patients radiotherapy plus chemotherapy. RESULTS: Two of the 14 patients treated by surgical removal of the tumor died. There was no mortality related to biopsy procedures. Patients treated with radiotherapy had 1-year, 2-year and 5-year survival rates of 66%, 41.6% and 16.6%, compared to 87.5%, 62.5% and 50%, respectively, for patients who received radiotherapy and chemotherapy. CONCLUSIONS: At present, there is no definite treatment for these highly malignant brain tumors. The most favorable results seem related to biopsy followed by radiotherapy plus chemotherapy versus surgical removal, which is related to a high risk of severe postoperative deficit for both the deep location and infiltrating nature of these lesions.
AIMS AND BACKGROUND: Primary CNS lymphomas are uncommon tumors in immunocompetent patients. We describe the radiological features that should orient towards performing a biopsy and analyze the results in our series of patients. METHODS: We reviewed 22 immunocompetent patients with primary central nervous system lymphoma admitted in our Institute between 1977 and 1997. The follow-up period ranged from 2 months (patient deceased) to 69 months. Fourteen patients underwent surgical removal of the tumor and the remainder a biopsy. All patients received radiotherapy and 8 patients radiotherapy plus chemotherapy. RESULTS: Two of the 14 patients treated by surgical removal of the tumor died. There was no mortality related to biopsy procedures. Patients treated with radiotherapy had 1-year, 2-year and 5-year survival rates of 66%, 41.6% and 16.6%, compared to 87.5%, 62.5% and 50%, respectively, for patients who received radiotherapy and chemotherapy. CONCLUSIONS: At present, there is no definite treatment for these highly malignant brain tumors. The most favorable results seem related to biopsy followed by radiotherapy plus chemotherapy versus surgical removal, which is related to a high risk of severe postoperative deficit for both the deep location and infiltrating nature of these lesions.
Authors: Ali I Rae; Amol Mehta; Michael Cloney; Connor J Kinslow; Tony J C Wang; Govind Bhagat; Peter D Canoll; George J Zanazzi; Michael B Sisti; Sameer A Sheth; E Sander Connolly; Guy M McKhann; Jeffrey N Bruce; Fabio M Iwamoto; Adam M Sonabend Journal: Neurosurgery Date: 2019-04-01 Impact factor: 4.654
Authors: Jonathan Yun; Jingyan Yang; Michael Cloney; Amol Mehta; Suprit Singh; Fabio Massaiti Iwamoto; Alfred I Neugut; Adam M Sonabend Journal: Front Neurol Date: 2017-09-12 Impact factor: 4.003
Authors: Pierre Ferrer; Pablo Barbero; Gonzalo Monedero; Anna Lo Presti; Bartolome Bejarano; Juan Ramon Penanes Journal: Surg Neurol Int Date: 2020-05-23